Drug intelligence / Profile preview

KinoPharma dengue antiviral

Development stage: Preclinical
Lead developer: KinoPharma
Modality: Small Molecules

Overview

KinoPharma's dengue antiviral is a preclinical-stage therapeutic candidate currently under development for the treatment of Dengue Fever. Developed by the Japanese biotechnology company KinoPharma, the asset is part of a broader pipeline focused on small molecule antivirals targeting both DNA and RNA viruses. The drug is designed to exert direct antiviral activity against the Dengue virus (DENV), though its specific molecular mechanism—such as the inhibition of viral entry, RNA-dependent RNA polymerase, or viral protease—has not been publicly disclosed. The program is currently in the early stages of development, categorized as preclinical.

Other names: Dengue TreatmentDengue virus antiviral

Targets

SRPK1 (Serine/arginine-rich protein-specific kinase 1)

Beyond the preview

Go deeper on KinoPharma dengue antiviral.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KinoPharma dengue antiviral.

Explore the full profile